论文部分内容阅读
AIM:To examine the efficacy and safety of otilonium bromide(OB)in treatment-sensitive functional irritable bowel syndrome(IBS)clinical parameters.METHODS:Ninety-three patients(44.8±12.6 years,69%female)with IBS symptoms complying with RomeⅡcriteria p